#436
|
|||
|
|||
visual RVD >2.5 & <4.25mm; visual lesion length <24mm - ýòî îêîëî 80% âñåõ ñòåíîçîâ, åñëè àíãëèéñêàÿ ôðàçåîëîãèÿ äîïóñêàåò ñëîâî Workhorse ïðèìåíèòåëüíî ê òîìó, ÍÀÄ ÷åì ìû ðàáîòàåì, à íå òîëüêî ê òîìó, ×ÅÌ ìû ðàáîòàåì, òî ÿ áû ôîðìóëèðîâàë ïðåäëîæåíèå ñ ôðàçîé "îñíîâíîé õëåá"
Àïïåíäèöèò - "îñíîâíîé õëåá" äåæóðíîãî õèðóðãà. Ïåðåëîì ëó÷à â òèïè÷íîì ìåñòå - "îñíîâíîé õëåá" âðà÷à òðàâìîïóíêòà. Ñòåíîçû ñîñóäîâ >2.5 & <4.25mm; äëèíîé <24mm - îñíîâíîé õëåá èíòåðâåíöèîííîãî êàðäèîëîãà. Åñëè "æàíð ïðîèçâåäåíèÿ" òàêîé ïåðåâîä ïîçâîëÿåò |
#437
|
|||
|
|||
|
#438
|
|||
|
|||
The first study, TAXUS PERSEUS Workhorse (A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions), will evaluate the safety and efficacy of the TAXUS Element Stent compared to Boston Scientific's first generation drug-eluting stent, the TAXUS® Express2™ Stent. This study will evaluate 1,264 patients with "workhorse" lesions from 2.75 to 4.0 millimeters. The primary endpoint of the workhorse study is target lesion failure (TLF) at 12 months, and its secondary endpoint is in-segment percent diameter stenosis at nine months.
Ñóäÿ ïî òàêîé ïîñòàíîâêå âîïðîñà ìíå êàæåòñÿ àäåêâàòíûì "íàèáîëåå ÷àñòûå" |
#439
|
||||
|
||||
Òåïåðü åùå áîëüøå ïîõîæå íà íàèìåíîâàíèå êàëèáðà ñîñóäîâ. Ìåëêèå, êðóïíûå, à ìåæäó íèìè ïðîìåæóòî÷íûå - ðàáî÷àÿ ëîøàäêà è ëîøàäêà.
Èíòåðåñíî áû äîæäàòüñÿ ìíåíèÿ àíãèîõèðóðãîâ. ×òî êàñàåòñÿ íàèáîëåå ÷àñòûõ, ïî âñåé âèäèìîñòè - íàèáîëåå ÷àñòî ïîðàæàåìûå. |
#440
|
|||
|
|||
Óâàæàåìûå êîëëåãè! Áîëüøîå ñïàñèáî çà îêàçàííóþ ïîìîùü.
Îòäåëüíûå ñëîâà ïåðåâîæó, ñìûñë íå ïîíèìàþ. Ðå÷ü èäåò î ïîêàçàíèÿõ ê ïðèìåíåíèþ íîñîâûõ êàíþëü äëÿ êèñëîðîäà: Patients with adequate spontaneous respiratory effort, airway protective mechanism, and tidal volume è åùå- ventilatory drive...
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |
#441
|
|||
|
|||
À ïîëíóþ öèòàòó (ôðàãìåíò/àáçàö) - ìîæíî?
|
#442
|
|||
|
|||
The nasal cannula (Figure 1) is a low-flow oxygen administration system designed to add oxygen to room air when the patient inspires.
Indications: Patients with adequate spontaneous respiratory effort, airway protective mechanism, and tidal volume Patients with arterial oxyhemoglobin saturation <94% Patients with minimal respiratory or oxygenation problems Patients who cannot tolerate a face mask Never withhold oxygen from patients who have respiratory distress and severe hypoxemia simply because you suspect a hypoxic ventilatory drive. If oxygen administration depresses respiration, support ventilation. |
#443
|
|||
|
|||
Âîçìîæíî ï.1
- Ïàöèåíòàì ñ àäåêâàòíûì ñàìîñòîÿòåëüíûì äûõàíèåì â êà÷åñòâå ñïîñîáà çàùèòû äûõàòåëüíûõ ïóòåé è îáåñïå÷åíèÿ àäåêâàòíîãî ïîòîêà âîçäóõà; ... hypoxic ventilatory drive - ? ÿ ïàñ... |
#444
|
|||
|
|||
Êàê âàðèàíò, ìîæíî ó÷èòûâàòü è âîçìîæíîñòü îïå÷àòêè.
Êñòàòè, â êàêèõ ñèòóàöèÿõ ("óãíåòåíèå äûõàòåëüíîãî öåíòðà"?) íàäî ïðåêðàòèòü ïîäà÷ó êèñëîðîäà? withhold oxygen from patients who have respiratory distress and severe hypoxemia simply because you suspect a hypoxic ventilatory drive |
#445
|
|||
|
|||
Ïî-âèäèìîìó, òà ñèòóàöèÿ, êîãäà îòñòàâàíèå â ÿçûêå íàóêè ïðèâîäèò ê íåîáõîäèìîñòè çàèìñòâîâàíèÿ èëè ñëîæíûõ îáúÿñíåíèé (ðåãóëÿöèÿ äûõàòåëüíîãî öåíòðà ñ ïðåèìóùåñòâåííûì èñïîëüçîâàíèåì ðåöåïòîðîâ Î2 - ??).
ß ïðî òàêóþ øòóêó è íå ñëûõèâàë, íî îíà, âðîäå áû, åñòü - áåç îïå÷àòîê ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ], [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]). Êàê âàðèàíò âñòðåòèëîñü "ãèïîêñè÷åñêèé "drive" ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]), íî ýòî òîæå íå îò õîðîøåé æèçíè. Èëè âîò åùå âàðèàíò ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]): "Central respiratory control (respiratory drive)" - ñòàëî áûòü, "ãèïîêñè÷åñêèé" òèï êîíòðîëÿ äûõàíèÿ... Òîãäà âïîëíå ëîãè÷íî ñêëàäûâàåòñÿ: Öèòàòà:
|
#446
|
|||
|
|||
 îòíîøåíèè ïóíêòà
Öèòàòà:
|
#447
|
|||
|
|||
Öèòàòà:
* Öèòàòà:
|
#448
|
|||
|
|||
Öèòàòà:
Ï.Ñ. Ñ àíãëèéñêîãî íà àçåðáàéäæàíñêèé. Åñëè ó÷åñòü, ÷òî èç òðåõ ÿçûêîâ ÿ ëó÷øå âñåãî çíàþ ðóññêèé... Öèòàòà:
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |
#449
|
|||
|
|||
Ñïàñèáî!
Êñòàòè, ïîèñê ÿ íà÷èíàë âîò ñ ýòîé ñòðàíèöû -äîêàçàòåëüíîñòü, âåðîÿòíî, íåâûñîêà, íî èçëîæåíî èíòåðåñíî [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#450
|
|||
|
|||
Ýòî òî÷íî "êîãäà îòñòàâàíèå â ÿçûêå íàóêè", êàê ñêàçàë óâàæàåìûé äîêòîð Ñàìèòèí:
"glottic"-1. îòíîñÿùèéñÿ ê ÿçûêó. 2. îòíîñÿùèéñÿ ê ãîëîñîâîé ùåëè. "supraglottic airways" äëÿ èíòóáàöèè- êóäà ââîäÿò òðóáêó? (ÿ òîæå ïðîøó ïðîùåíèÿ, ó àíåñòåçèîëîãîâ îñîáåííî).
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |